Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What impact does this have on teflaro's competition?Is lorazepam addictive when used for insomnia?Lorazepam manufacturer?Which drug stops rhythmic muscular contraction originating the dorsal ganglia or other peripheral nerves better—carbamazepine or lacosamide?Is cosentyx dosage adjustment necessary for psa?
See the DrugPatentWatch profile for ibrance
How does ibrance interact with letrozole in breast cancer treatment? Ibrance, also known as palbociclib, is a targeted therapy used in combination with hormones like letrozole to treat hormone receptor-positive (HR+) breast cancer [1]. Letrozole, an aromatase inhibitor, works by decreasing estrogen levels, which can fuel cancer growth. Ibrance, on the other hand, specifically targets the cyclin-dependent kinases (CDK) 4 and 6 enzymes, halting cancer cell growth and proliferation [2]. By combining these two treatments, patients with HR+ breast cancer may experience improved treatment outcomes and delayed disease progression [3]. What clinical trials have investigated this combination? Phase III clinical trials have explored the efficacy and safety of combining ibrance with letrozole in patients with HR+ metastatic breast cancer. For example, the PALOMA-2 trial demonstrated that ibrance plus letrozole significantly prolonged progression-free survival compared to letrozole alone [4]. Why might certain patients be considered for this treatment combination? Patients with estrogen receptor-positive (ER+) and HER2-negative breast cancer who have received no more than one prior endocrine therapy may benefit from this combination [5]. However, it's crucial to note that not all patients with HR+ breast cancer will be suitable for treatment with ibrance and letrozole. Your healthcare provider will assess your individual situation and medical history before recommending this combination. What are possible side effects to be aware of? Both ibrance and letrozole can cause common side effects like nausea, diarrhea, fatigue, and rash [6]. It's essential to discuss the potential risks and benefits of this combination with your healthcare provider. Additionally, you should be aware of the specific side effects associated with ibrance, such as low blood counts and liver toxicity [7]. Does the patent for ibrance affect access to this treatment combination? The ibrance patent is owned by Pfizer and is set to expire [8]. However, the exclusive rights granted by the patent may impact the availability and affordability of this treatment, potentially delaying the entry of generic or biosimilar versions. Sources: [1] https://www.cancer.gov/about-cancer/treatment/drugs/palbociclib [2] https://www.drugpatentwatch.com/drug/palbociclib [3] DOI: 10.1200/JCO.2015.61.2601 [4] DOI: 10.1200/JCO.2015.63.1730 [5] https://www.cancer.gov/about-cancer/treatment/drugs/palbociclib-protocol.pdf [6] https://www.pfizer.com/news/medicalinformation/ibrance.htm [7] https://www.drugwatch.com/ibrance-side-effects/ [8] https://www.drugpatentwatch.com/patent/US/US10114213
Other Questions About Ibrance :